MC  Vol.3 No.1 , January 2014
Intraperitoneal distribution of alginate microcapsules in mice
ABSTRACT

Introduction: Improved drug delivery mechanisms for the treatment of residual peritoneal cancer cells following cytoreduction surgery are needed. Alginate microcapsules are a potentially useful mechanism for delivery of bioengineered cells, but when injected into the peritoneum, their distribution and properties are not well described. Methods: Aliquots of 300, 600 or 1200 microcapsules were injected into the peritoneum of 81 mice. Mice were sacrificed at 6, 12, 18, and 48 days and laparotomy was performed to quantify the distribution of microspheres. Results: The injections were well tolerated for up to 48 days. No peritoneal adherence or inflammatory reaction was noted to the microcapsules. Injection of 1200 microcapsules resulted in a better overall persistence and widespread peritoneal distribution at up to 48 days. The volume of fluid used for injection of the microcapsules did not affect their distribution or persistence. Conclusion: The intraperitoneal injection of alginate microspheres allows wide and persistent distribution throughout the abdominal cavity. The next step is to test the distribution of microcapsules when delivered following surgery in a rodent model.


Cite this paper
Dagbert, F. , McConnell, Y. , Carmona, E. , Sideris, L. , Hallé, J. and Dube, P. (2014) Intraperitoneal distribution of alginate microcapsules in mice. Modern Chemotherapy, 3, 1-4. doi: 10.4236/mc.2014.31001.
References
[1]   Elias, D., Gilly, F., Boutitie, F., Quenet, F., Bereder, J.-M., Mansvelt, B., Lorimier, G., Dubè, P. and Glehen, O. (2010) Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: Retrospective analysis of 523 patients from a multicentric French study. Journal of Clinical Oncology, 28, 63-68.
http://dx.doi.org/10.1200/JCO.2009.23.9285

[2]   Glehen, O., Gilly, F.N., Boutitie, F., Bereder, J.M., Quenet, F., Sideris, L., Mansvelt, B., Lorimier, G., Msika, S. and Elias, D. (2010) Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: A multi-institutional study of 1290 patients. Cancer, 116, 5608-5618.
http://dx.doi.org/10.1002/cncr.25356

[3]   Saxena, A., Yan, T.D. and Morris, D.L. (2010) A critical evaluation of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis. World Journal of Surgery, 34, 70-78.
http://dx.doi.org/10.1007/s00268-009-0206-0

[4]   Koppe, M.J., Boerman, O.C., Oyen, W.J. and Bleichrodt, R.P. (2006) Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Annals of Surgery, 243, 212-222.
http://dx.doi.org/10.1097/01.sla.0000197702.46394.16

[5]   Van der Speeten, K., Stuart, O.A., Mahteme, H. and Sugarbaker, P.H. (2010) Pharmacology of perioperative 5-Fluorouracil. Journal of Surgical Oncology, 102, 730-735. http://dx.doi.org/10.1002/jso.21702

[6]   Venturini, M. (2002) Rational development of capecitabine. European Journal of Cancer, 38, 3-9.
http://dx.doi.org/10.1016/S0959-8049(01)00414-2

[7]   Aprile, G., Mazzer, M., Moroso, S. and Puglisi, F. (2009) Pharmacology and therapeutic efficacy of capecitabine: Focus on breast and colorectal cancer. Anticancer Drugs, 20, 217-229.
http://dx.doi.org/10.1097/CAD.0b013e3283293fd4

[8]   Marchetti, S., Chazal, M., Dubreuil, A., Fischel, J.L., Etienne, M.C. and Milano, G. (2001) Impact of thymidine phosphorylase surexpression on fluoropyrimidine activity and on tumour angiogenesis. British Journal of Cancer, 85, 439-445. http://dx.doi.org/10.1054/bjoc.2001.1908

[9]   Dusseault, J., Leblond, F.A., Robitaille, R., Jourdan, G., Tessier, J., Ménard, M., Henley, N. and Hallé, J.-P. (2005) Microencapsulation of living cells in semi-permeable membranes with covalently cross-linked layers. Biomaterials, 26, 1515-1522.
http://dx.doi.org/10.1016/j.biomaterials.2004.05.013

[10]   Jourdan, G., Dusseault, J., Benhamou, P.Y., Rosenberg, L. and Hallé, J.P. (2011) Co-encapsulation of bioengineered IGF-II-producing cells and pancreatic islets: Effect on beta-cell survival. Gene Therapy, 18, 539-545.
http://dx.doi.org/10.1038/gt.2010.166

[11]   Meyers, M.A. (1973) Distribution of intra-abdominal malignant seeding: Dependency on dynamics of flow of ascitic fluid. American Journal of Roentgenology, 119, 198-206. http://dx.doi.org/10.2214/ajr.119.1.198

[12]   Morgan, A., Collier, C. and Kellington, J. (1993) Distribution of glass fibers in the peritoneal cavity of the rat following administration by intraperitoneal injection. Journal of Toxicology and Environmental Health, 38, 245-256. http://dx.doi.org/10.1080/15287399309531716

[13]   Robitaille, R., Dusseault, J., Henley, N., Desbiens, K., Labrecque, N. and Hallé, J.-P. (2005) Inflammatory response to peritoneal implantation of alginate-poly-L-lysine microcapsules. Biomaterials, 26, 4119-4127.
http://dx.doi.org/10.1016/j.biomaterials.2004.10.028

 
 
Top